
    
      -  Prospective, open-labeled Clinical Investigation enrolling patients with visually
           estimated nominal vessel diameter of 3.0 mm and lesion length ≥ 8 mm receiving a single
           3.0 x 12 mm BVS Everolimus Eluting CSS containing 98 microgramme per cm² of surface
           area. Lesion length will be expanded to≥ 14 mm in length by visual estimation when 3.0 x
           18 mm stent is available.

        -  Angiographic, Intravascular Ultrasound (IVUS), Intravascular Ultrasound- virtual
           histology (IVUS-VH) and Palpography follow-up will be carried out in all patients at 180
           days and 2 years following the index procedure

        -  Optical Coherence Tomography (OCT) follow-up at 180 days and 2 years will be carried out
           in a subset of up to 10 patients in Cohorts A and B respectively who are enrolled in
           pre-determined clinical site(s)

        -  Multi-slice Spiral Computed Tomography (MSCT) is an optional procedure which may be
           carried out at 18 months post procedure and again between 4 and 5 year follow up.

        -  Additionally, coronary vasomotion test may be done at 2 years post procedure

      Single patient Cohort of 30.

      Pipeline products. Currently in development at Abbott Vascular. Not available for sale.
    
  